Did you attend this webinar? Get your certificate
Questions/answers on the Session 2 - General Overview of Fibrinolysis
A1. While epidemiological investigations suggest that FXIII antigen, activity, and/or genotype may influence thrombosis risk (with considerable discordance among studies), FXIII assay in the clinical practice is recommended for identification of FXIII deficiency.
A2. All conditions characterized by increased clotting activation, including VTE and DIC, would theoretically benefit from fibrin monomer (FM) testing, as FM represents an early and specific marker of fibrin formation. In septic patients, in particular, the combination of D-dimer and fibrin monomer was shown to improve risk stratification over D-dimer alone. However, while promising, FM assay presents several limitations (e.g., cut-off values, timing of FM measurement) and thus its place as prognostic marker for any given conditions needs to be validated by ad hoc prospective studies.
A3. FDPs and D-dimer are increased in many conditions and their meaning may change according to the specific condition. For example, we found that D-dimer levels in sepsis correlated better with plasmin generation than with thrombin formation, which is the opposite of what happens in VTE patients. Thus, due to the lack of specificity, the assay of FDPs, particularly D-dimer, may provide valuable information to clinicians only in the well-known conditions for which the utility of the assay has been validated by clinical studies, namely VTE exclusion (in combination with clinical probability), DIC diagnosis (as part of DIC scores) and likely in determining the duration of anticoagulation.
A4. Elevated levels of PAI-1 have been documented by a huge number of studies as a major mechanism of fibrinolysis inhibition in many conditions associated with venous or arterial thrombosis, or DIC. Still, neither PAI-1 nor t-PA is included in the panel of assays to assess thrombosis risk or prognosis (e.g., sepsis) likely because of the lack of standardization and reference values, methodological aspects, and other limitations. Concerning plasminogen and alpha2-antiplasmin, their assay in the clinical laboratory is indicated when a deficit of one these factors is suspected.
A5. Our study on corrected DDimer is a proof of concept that adjustments for plasmin and thrombin generation might provide a better picture on what is going on in vivo. While encouraging, our data are insufficient to propose corrected DDimer as an alternative to currently used tests. Thus, regular labs should stick to the classical scores for DIC diagnosis and to clinical variables (SOFA, SAPS II).